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{School ofThe Asia Paciﬁc Cohort Studies Collaboration (APCSC) was established in the late 1990s when there was
a distinct shortfall in evidence of the importance of risk factors for cardiovascular disease in Asia. With
few exceptions, most notably from Japan, most of the published reports on cardiovascular disease in the
last century were from Western countries, and there was uncertainty how far etiological associations
found in the West could be assumed to prevail in the East. Against this background, APCSC was set up as
a pooling project, combining individual participant data (about 600,000 subjects) from all available
leading cohort studies (36 from Asia and 8 from Australasia) in the region, to ﬁll the knowledge gaps. In
the past 10 years, APCSC has published 50 peer-reviewed publications of original epidemiological
research, primarily concerned with coronary heart disease, stroke, and cancer. This work has established
that Western risk factors generally act similarly in Asia and in Australasia, just as they do in other parts of
the world. Consequently, strategies to reduce the prevalence of elevated blood pressure, obesity, and
smoking are at least as important in Asia as elsewhered and possibly more important when the vast size
of Asia is considered. This article reviews the achievements of APCSC in the past decade, with an
emphasis on coronary heart disease.The Asia Paciﬁc Cohort Studies Collaboration
(APCSC) was established at the end of the last
century, when there was a plethora of high-quality
evidence of the effects of several risk factors on cardio-
vascular disease (CVD) fromOccidental populations,
but scant evidence from Oriental populations [1].
This was despite CVD already being a leading cause
of death in Asia. However, the pattern of CVD was,
and still is, somewhat different in many Asian coun-
tries to European and North American countries.
Stroke is often more common than coronary heart
disease (CHD) in Asia, but not in the West, and
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lished “Western” CVD risk factors were known to
have very different distributions in Asiadfor
example, body mass index and cholesterol tend to
be lower in Asia. So there were reasons to doubt
that etiological associations conﬁrmed, and CVD
guidelines developed, in the West could be assumed
for Asian populations. With the huge, and aging,
populations in Asia, there was a clear need for reliable
evidence on the effects of risk factors to inform policy
makers in Asian countries and promote primary
prevention of CVD and other noncommunicable
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344underway, in Asia were not of a size (in terms of
numbers of people or numbers of events) to provide
the level of certainty required in estimates of associa-
tion. Even where numbers were of reasonable size
overall, they were not large enough to reliably evaluate
sex- and age-speciﬁc effects.
Hence,APCSCwas envisaged as a pooling project
of existing studies with the remit to provide reliable
evidence of the age-, sex-, and region-speciﬁc associ-
ations between classical Western risk factors and
CHD, stroke, and other leading causes of death in
the Asia-Paciﬁc region. At the outset it was realized
that a key output from the research would be a
comparison of the associations between risk factors
and diseases between theWestern parts of the region
(Australia and New Zealand: ANZ or Australasia)
and Asia. In this way, ANZ could act as an exemplar
of the West and thus allow East-West comparisons
within a single platform.
TH E S TUD I E S
Studies were eligible for inclusion in this project if
they: had a study population from the Asia-Paciﬁc
region; used a prospective cohort study design;
observed at least 5,000 person-years of follow-up;
recorded dates of birth (or ages at baseline);
recorded sex and blood pressure at baseline; and
recorded dates of death (or ages at death), where
appropriate. Studies were excluded if they: selected
subjects on the basis of a positive disease history
or diagnosis; or were judged to be of poor quality,
after consultation with local experts.
Using these criteria, studies were identiﬁed by
electronic searches and personal contacts, and prin-
cipal investigators were invited to join by sharing
their individual participant data on a range of base-
line sociodemographic variables and risk factors, as
well as events during follow-up. Ultimately this
led to the inclusion of 44 studies, 16 from mainland
China, 14 from Japan, 8 from Australia, 2 from
Taiwan, 2 from Singapore, and 1 each from Hong
Kong, New Zealand, South Korea, and Thailand.
Unfortunately, no eligible study was found, or was
willing to join, from the Indian subcontinent or
the Paciﬁc Islands. In addition to the basic require-
ments of providing data on potential risk factors at
baseline and deaths during follow-up, 16 of the 44
studies additionally provided repeat post-baseline
measurements of risk factors, 19 reported nonfatal
strokes, and 16 reported nonfatal CHD events.
The study is directed by an executive committee
withcross-regional coverage.Day-to-daymanagementis undertaken through a secretariat at theGeorge Insti-
tute in Australia.
PU B L I C A T I ON S
To date, APCSC has published 52 peer-reviewed
publications [1e52]. Apart from the initial protocol
[1], all were published from 2003 to 2012. These can
be grouped into papers that report (at least primarily)
on the following: single risk factor associations
for CVD [2e13,15,18e20,24,28,38,46,47,49,51];
interactions between modiﬁable risk factor associa-
tions for CVD [14,30,31,34,37,40,41,48,50]; the
national prevalence of risk factors and attributable risks
for CVD [17,23,25,29,35]; risk factor associations for
cancer [21,26,27,32,36,42e45,52]; risk factors for
other diseases (diabetes [16] and kidney [39]); and
smoking and all-cause mortality [33]. This totals 50
primary research papers in the last decade. In addition,
a proﬁle of the study was published in 2006 [22].
METHODS
Every study has provided individual participant
data, and analyses are performed taking all the
data as a single entity (sometimes called a “1-step
method” for meta-analysis). Compared with the
2-step method that is necessary when pooling pub-
lished parameters, individual participant data has
the advantage of allowing greater ﬂexibility in model
building, especially when interactions are included;
conversely, it is less well suited to consideration of
heterogeneity between studies. Associations between
risk factors and outcomes are estimated using Cox
proportional hazards models, stratiﬁed [53] by study
and sex. All results are at least age-adjusted; most
publications show results after adjustment for other
risk factors that are potential confounders. Associa-
tions of all continuous variables are adjusted for
regression dilution using information from repeat
measures [53] from those studies within APCSC
that have appropriate data. The ﬂoating absolute
risk technique [53] is used to produce conﬁdence
intervals around the point estimates of hazard ratios.
Typically, associations are estimated both after
grouping the risk factor into ordinal groups, such as
its quarters, and when taking the variable in its
continuous form. Interactions between risk factors
are tested by adding cross-multiplication terms to
the Cox models. Results from Asia and ANZ are
compared, again, by adding cross-multiplication
terms (here, involving region) to Coxmodels. Attrib-
utable risks are estimated, by country, using nationally
Table 1. Summary statistics for APCSC participants aged 20 years or more
Asia (n ¼ 500,819) Australia and New Zealand (n ¼ 98,790)
Baseline variables
Women, % 33.7 45.7
Age, yrs (range) 45.0  9.5 (20e107) 53.2  14.4 (20e104)
Systolic blood pressure, mm Hg 121.3  17.7 136.9  22.1
Diastolic blood pressure, mm Hg 77.7  10.7 79.2  12.7
Total cholesterol (mmol/l) 4.9  0.98 5.6  1.13
HDL cholesterol (mmol/l) 1.35  0.38 1.45  0.38
Triglycerides (mmol/l) 1.44  1.04 1.41  1.07
Body mass index, kg/m2 22.9  2.9 26.3  4.3
Smoking, % 41.6 17.6
Diabetes, % 3.4 4.2
Number of deaths (median follow-up) (6.1 yrs) (8.3 yrs)
Total 17,648 7,897
CHD 1,341 1,855
Stroke* 2,851 613
Hemorrhagic stroke 1,276 114
Ischemic stroke 591 79
Values are mean  SD unless otherwise indicated. CHD, coronary heart disease; HDL, high-density lipoprotein.
* Many strokes were not classiﬁed by subtype.
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345representative (not APCSC) data for prevalence
[17,23,25,29] or distributions [35] and APCSC
data for estimated relative risks.
R E SU L T S
Altogether, APCSC includes 600,443 subjects, of
whom almost 600,000 are aged 20 years or over
(Table 1). The average levels of risk factors tend to
be worse in ANZ than in Asia, except for smoking,
which is more common in Asia; although this hides
a huge differential between the sexesdsmoking is
typically common among men, but rare among
women, in Asia [17]. As expected, the fatal stroke/
CHD ratio is much higher in Asia (around 2:1)
than in ANZ (around 1:3) and the fatal hemor-
rhagic/ischemic stroke ratio is also higher in Asia
(around 2:1) than in ANZ (around 3:2).
Primary associations. Figure 1 shows age-adjusted
associations for 6 leading risk factors for fatal
CHD. Allowing for random error, the associations
seen for all 6 risk factors are very similar in Asia and
ANZ. Only for systolic blood pressure (SBP) was
there evidence of an interaction (P¼ 0.002). For total
cholesterol (TC), high- density lipoprotein choles-
terol, triglycerides, and SBP, the relationship with
fatal CHD was approximately log-linear, with a
shallower slope for SBP in ANZ than in Asia. For
body mass index (BMI), the shape of the relationship
was clearly nonlinear in ANZ; in Asia, the sameJ-shape was suggested, but not as clearly. There was
also a clear dose-response relationship for smoking
status in both regions: never smokers having the least
and current smokers the most risk of a fatal CHD.
The hazard ratio for diabetes compared with no
diabetes was, similarly, much the same (around 2) for
both subregions (p for interaction ¼ 0.42). Multiple
adjusted results showed much the same similarities,
with the same exception of a signiﬁcant difference for
SBP between regions [11].
Interactions between risk factors. The APCSC
papers on interactions between the major modiﬁable
cardiovascular risk factors, published to date, have
reported on the joint risks for CHD and stroke
for all but one of the 10 2-way combinations of
BMI, diabetes, smoking, SBP, and TC. As above,
here only results for CHD will be summarized.
In 5 (diabetes and BMI [48], diabetes and
smoking [41], diabetes and SBP [31], diabetes and
TC [30], SBP and smoking [34]) of the 9 combina-
tions studied, there was no evidence (P > 0.10) of
(multiplicative) interaction.Hence, when any of these
2-way combinations of risk factors are taken together,
the APCSC results suggest that the effect of one risk
factor can broadly be assumed to act the same what-
ever the level of the other risk factor. All the same,
having a combination of 2 “bad” levels always appears
to be worse than having just a single bad level.
In 2 combinations of risk factors (smoking and
BMI [40], smoking and TC [37]), there was
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Fig. 1. Hazard ratios (95% conﬁdence intervals) for fatal coronary heart disease (CHD) for 6 major risk factors in Asia Paciﬁc Cohort
Studies Collaboration (APCSC) subjects who were domiciled in either Asia or Australia/New Zealand (ANZ). Continuous variables were
corrected for regression dilution bias and grouped into ﬁfths or, when data were relatively sparse, quarters. The group with the
lowest values was taken as the reference (hazard ratio [ 1), except for high-density lipoprotein (HDL) cholesterol, for which the
group with the highest values was used. Hazard ratios for a unit difference and p values for a regional interaction between the index
risk factor and the hazard for fatal CHD are each shown in text boxes. Note that these results sometimes differ from those in earlier
publications because the most recent version of the APCSC database is used here. BMI, body mass index; SBP, systolic blood pressure;
HDL, high-density lipoprotein; TG, triglycerides.
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346evidence of synergism. Among current smokers
there was a 13% higher risk of CHD associated
with a 2 kg/m2 higher level of BMI compared
with a 9% additional risk amongst nonsmokers
(P ¼ 0.04 for the interaction). Similarly, among
current smokers there was a 54% higher risk of
CHD for a 1-SD (1.06 mmol/l) higher level of
TC compared with a 38% additional risk for
nonsmokers (P ¼ 0.02 for the interaction). Hence,concurrent smoking seems to exacerbate the ill
effects of high levels of both adiposity and blood
cholesterol level. If this is more widely true, it
suggests that application of standard cardiovascular
risk scores may underestimate risk for smokers.
A corollary is that quitting smoking with either
lowering of SBP or better control of lipids may
have even greater beneﬁt than would be expected
from past projections.
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Fig. 2. Fatal coronary heart disease (CHD) and stroke population attributable risks for 3 major risk factors in 8 countries or regions
within the Asia-Paciﬁc region. China, mainland China; HK, Hong Kong; NZ, New Zealand.
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347In the ﬁnal 2 cases (SBP and BMI [50], SBP
and TC [14]), there was evidence of antagonism.
The effects of SBP on CHD, although always
substantial and log-linear, tended to diminish as
BMI increased (P ¼ 0.01 for the interaction). For
example, a 10-mm Hg higher SBP was associated
with a 27% higher risk among people with "healthy"
BMI (18.5 to 22.9 kg/m2) compared with a 17%
higher risk among overweight people (BMI: 25 to
29.9 kg/m2). Similarly, the log-linear effects of
SBP diminished systematically as TC level
increased (P < 0.001 for the interaction). For
example, a 10-mm Hg higher SBP was associated
with a 34% higher risk among those with TC
<4.75 mmol/l compared with 21% among those
with TC >6.25 mmol/l. Thus, though not under-
mining the importance of these risk factors, this
suggests that when the effects of SBP are considered
along with either BMI or TC, some allowance
should be made for mutual attenuation of effects.
Comparison of these contrasting results should
take account of the relatively low power when testsare performed on dichotomous variables, such as
diabetes and smoking. More generally, although
APCSC has a large sample, which allows us to reli-
ably examine the effect modiﬁcation of one risk
factor on another, it is still not large enough for
more detailed analyses of interactions involving
more than two risk factors or to reliably compare
the interaction effects of modiﬁable risk factors
across region, age, or sex groups. Furthermore,
unlike in Figure 1, fatal and nonfatal events were
combined in the analyses testing interactions to
increase the available power. With more data, reli-
able conclusions for 2-way interactions would be
possible for fatal CHD, and fatal stroke, alone.
Attributable risk. Figure 2 shows estimates of
attributable risks (AR) for CHD, hemorrhagic and
ischemic stroke mortality for 8 selected countries in
the Asia-Paciﬁc region, and 3 selected risk factors,
using the most recent national data available when
the APCSC papers were published (2006/2007).
Blood pressure is an especially strong determinant of
both the major stroke subtypes, but most particularly
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348hemorrhagic stroke, which has AR approaching 50%
in some countries. Differences between countries
were not great, reﬂecting the widespread importance
of high blood pressure for all CVD across the entire
Asia-Paciﬁc region. For overweight or obesity (BMI
of 30 kg/m2 or more), ARs were smaller for
hemorrhagic stroke than for either CHD or ischemic
stroke, and both Australia and New Zealand had
much higher ARs than any Asian country for which
data were available. As already noted, the prevalence
of smoking for men is much higher than for women
in many Asian countries; hence, ARs are presented
here separately for women and men. Due to these
differences in prevalence in Asia, and the contrasting
situation in ANZ where the prevalence of smoking is
very similar between sexes, the pattern of AR by
country goes in opposite directions by sex. For
women, ARs are higher in ANZ than in Asia, but for
men they are lower. Hemorrhagic stroke has lower
ARs due to smoking than those for CHD or
ischemic stroke; the AR for the latter pair are broadly
similar.
D I S CU S S I ON
This synopsis has reviewed some of the previously
published results from APCSC, with a particular
focus on CHD. Further details are available from
the published papers. After a decade of research,
APCSC has a considerable portfolio of results and
recommendations that have been inﬂuential in
setting national guidelines and have contributed
results to international forums, such as the World
Health Organization’s Global Burden of Disease
study [54] and the Institute of Medicine’s initiative
to improve global cardiovascular health [55]. The
research has not only greatly extended knowledge of
chronic disease risk factors in Asia, but also has
produced more precise estimates of the effects of
some risk factors than had previously been available,
for example, on triglycerides [7]. Due to the relatively
low incidence inWestern populations, risk factors for
stroke, and particularly hemorrhagic stroke, have not
been studied as thoroughly as CHD has been. The
Asian studies in APCSC had a high frequency of
stroke events; thus, APCSC has contributed impor-
tantly to epidemiological knowledge about stroke
and its risk factors.
Moreover, in addition to producing valuable
region-speciﬁc estimates of associations between
risk factors and chronic disease, the large number
of women (well over 200,000) included in the
collaboration has enabled us to reliably explore sexdifferences in the relationships between risk factors
and outcomes. For example, several papers have
shown higher relative risks associated with diabetes
and cigarette smoking for CHD and other chronic
conditions in women than in men. The APCSC
ﬁndings have contributed to the growing body of
evidence suggesting that there are fundamental
sex-differences in how certain risk factors exert their
effects on subsequent chronic disease risk [56,57].
APCSC has, undoubtedly, been a trendsetting
project. APCSC researchers are based in 9 countries
or regions, speak at least 5 major primary languages,
and are from several professionsdpredominantly
clinical, statistical, and epidemiological. It is a tribute
to all concerned that such a disparate group of
researchers has collaborated so successfully and
achieved so much in a comparatively short space
of time. Perhaps most importantly, the APCSC
has been an important focus for the training of
Asian researchers. APCSC workshops have been
held in China, South Korea, and Hong Kong and
have been attended by students and healthcare
professionals from the region that sought to beneﬁt
from an intensive course in cardiovascular epidemi-
ology. These courses focused on the innovative statis-
tical methods used in APCSC, including modern
methods in meta-analysis. Furthermore, APCSC
still has valuable, yet-untapped, resources with exten-
sive data on risk factors, such as alcohol consumption
and socioeconomic status, yet to be analyzed. An
extensive program of future research has been
mapped out to include greater use of the data as a prac-
tical basis for the evaluation of contemporary meth-
odology in biostatistics, for example, continuing the
use of these data to compare methods for missing
value imputation [58].
APCSC is not, however, without its drawbacks,
most of which stem from the use of existing datasets.
First, many of the cohorts began in the 1980s; CVD
treatment and risk factor proﬁles have changed
considerably in the many Asian countries that are
undergoing economic and epidemiological transi-
tions. Second, reporting of risk factors is not always
consistent, both in terms of coverage (high-density
lipoprotein cholesterol, for example, is only recorded
in 25 of the 44 cohorts) and methodology. This is
a particular problemwhen analyzing nonclinical vari-
ables, such as alcohol and social class, which are
recorded differently in different geo-ethnic popula-
tions. Third, repeat measurements are only available
from a minority of cohorts; even then, the frequency
of remeasurement is not consistent, so that only
limited longitudinal analyses are possible. Fourth,
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349only one study had a biobank available for use by the
collaboration, so we have been unable to reliably
analyze novel biomarkers, such as C-reactive protein.
Fifth, outcomes were recorded in several different
ways, including by contacting subjects, or their rela-
tives, and record linkage. Lack of information on
nonfatal outcomes frommany cohorts lowered statis-
tical power and could have introduced bias when all
events were pooled in some analyses. The level of
disaggregation in cause of death also varies. Most
studies used International Classiﬁcation of Diseases
(ICD) codes, but without consistency in which
version was used, and although we were able to
harmonize all coding to ICD-9, this could also have
introduced a degree of bias in estimation. Differential
diagnoses are a particular problem for subtyping
stroke; for instance, not all studies had access to
imaging.
To solve some of these problems, a new Asian
collaboration in CVD, LIFECARE (Life Course
Study in Cardiovascular Disease Epidemiology)
[59], has been formed, involving longitudinal
studies in 4 countries. This has a common set ofquestions and scheduled repeat recording of risk
factor levels, as well as a biobank. However, it
remains to be seen whether funding will allow
hard outcomes to be collected, and, if so, whether
follow-up will be long enough to obtain precise esti-
mates. Perhaps the future lies more in using
routinely collected health system data to draw
epidemiological inferences. In this respect, Asia
could lead the world with the existing huge medical
insurance databases in South Korea that have
already been used for epidemiological analyses (the
Korean Heart Study; paper submitted) and Taiwan
(the Taiwan MJ Health study) [60].ACKNOWL EDGMENT S
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